antiviral therapy

MA
Pharma

RIGImmune subsumes Subintro in nasal drug delivery buyout

The deal positions the biotech to advance the development of novel RNA therapies and vaccine adjuvants for local mucosal delivery.
Nick Paul Taylor Sep 19, 2022 6:55am